Company / Net Income
Anixa Biosciences Inc Net Income History
FY2014-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$12.6M
FY2024
5-year range
-$14.2M / -$11.6M
FY2020-FY2024
Trend
+7.7%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income returned to growth in FY2024 after 2 years of decline, reaching -$13M.
Based on SEC 10-K filings.
-$13M in FY2024.
Improved from -$13M to -$13M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, net income increased 7.7% year-over-year.
- Peak net income was recorded in FY2016.
- Lowest net income in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.53 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$12.6M | +7.7% |
| FY2023 | -$13.6M | -4.9% |
| FY2022 | -$13.0M | -11.2% |
| FY2020 | -$11.6M | +18.2% |
| FY2019 | -$14.2M | -184.4% |
| FY2018 | -$5.0M | +0.1% |
| FY2017 | -$5.0M | -263.8% |
| FY2016 | -$1.4M | +85.6% |
| FY2015 | -$9.6M | +4.7% |
| FY2014 | -$10.1M | -36.6% |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026